Non-steroidal anti-inflammatory drugs for acute gout (Q24193584)

5

object named as

Désirée van der Heijde

0 references

Mihir D Wechalekar

object named as

Mihir D Wechalekar

2

0 references

author name string

Caroline MPG van Durme

1

0 references

Naomi Schlesinger

4

0 references

Robert BM Landewé

Cochrane Database of Systematic Reviews

6

0 references

publication date

16 September 2014

0 references

published in

0 references

cites work

Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Comparison of indomethacin and phenylbutazone in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Multicentre trial of naproxen and phenylbutazone in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

[Treatment of acute attacks of gout with naproxen-C 1674]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Celecoxib for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Rofecoxib for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Progress in measurement instruments for acute and chronic gout studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Systemic corticosteroids for acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

21 January 2018

Clinical practice. Gout

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Non-steroidal anti-inflammatory drugs for low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Outcome domains for studies of acute and chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

Flurbiprofen in the treatment of acute gout. A comparison with indomethacin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

Is gout associated with reduced quality of life? A case-control study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

Double-blind trial of feprazone and phenylbutazone in acute gout

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021

Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010120.PUB2

7 January 2021